Additional information
| Trade Name | TECERIS |
|---|---|
| Generic Name | ERIBULIN MESYLATE |
| Manufacturer | MYLAN |
| Drug Type | Oncology |
| Indication | Breast Cancer |
| Dosage Form | Injectible |
| Packaging | 2 ml in 1 vial |
TECERIS (Eribulin mesylate)-0.5 mg/ml
Eribulin Mesylate works by interfering with the microtubule structures which help the cancer cells to divide and multiply. This blocks the growth cycle (cell cycle) of cancer cells and eventually kills them.
Indicated for the treatment of patients with metastatic breast cancer, TECERIS (Eribulin mesylate) is used for those who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease
